Alto Neuroscience (ANRO) Revenue & Revenue Breakdown
Alto Neuroscience Revenue Highlights
00
Alto Neuroscience Revenue by Period
Alto Neuroscience Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $210.00K | - |
Alto Neuroscience generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Alto Neuroscience Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $394.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $372.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | - |
Alto Neuroscience generated - in revenue during Q3 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Alto Neuroscience Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMRN | Amarin | $204.59M | $48.56M |
| SLN | Silence Therapeutics | $43.26M | $224.00K |
| ACIU | AC Immune | $14.80M | - |
| KRRO | Korro Bio | $2.27M | $1.09M |
| CLLS | Cellectis | $755.00K | $4.53M |
| ALDX | Aldeyra Therapeutics | - | - |
| CTNM | Contineum Therapeutics, Inc. Class A | - | - |
| ANRO | Alto Neuroscience | - | - |
| DRTS | Alpha Tau Medical | - | - |
| DBVT | DBV | - | - |
| LRMR | Larimar Therapeutics | - | - |